Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 02, Issue-02, March-April, 2026

Hybrid Nanocomposites in Pharmacology: Multifunctional Platforms for Cancer and Inflammatory Disorders

Rajat Saxena[1*], Navneet Verma[1]

[1]Pharmacy Academy, Faculty of Pharmacy, IFTM University, Lodhipur Rajput Delhi Road, Moradabad, Uttar Pradesh, Pin- 244102

***Corresponding Author E-mail: rajatsaxena9410@gmail.com**

Abstract:

Hybrid nanocomposites have emerged as one of the most versatile and multifunctional platforms in modern pharmacology, offering unique opportunities to tackle the complex pathophysiology of cancer and inflammatory disorders. By integrating two or more organic, inorganic, polymeric, lipidic, or biological components into a single nanosystem, hybrid nanocomposites enable synergistic enhancements in drug loading, targeting precision, responsiveness to physiological stimuli, and therapeutic efficacy. Their ability to combine structural stability with dynamic functional properties makes them especially valuable in overcoming traditional treatment barriers such as multidrug resistance, uncontrolled inflammation, off-target toxicity, and limited bioavailability. Recent advancements in fabrication techniques—including chemical synthesis, microfluidic engineering, physical assembly methods, and green bioinspired strategies—have further expanded the design flexibility and clinical potential of these nanoplatforms. Hybrid nanocomposites are now being explored for targeted drug delivery, multimodal combination therapy, imaging-guided theranostics, immunomodulation, antioxidative therapy, and tissue regeneration. Despite their promise, challenges related to large-scale manufacturing, reproducibility, regulatory validation, and long-term safety still impede clinical translation. This review provides a comprehensive overview of the fundamentals, fabrication strategies, therapeutic applications, pharmacokinetics, and future opportunities of hybrid nanocomposites, emphasizing their transformative potential in next-generation cancer and inflammation management.

Keywords

Hybrid Nanocomposites; Multifunctional Drug Delivery; Cancer Therapy; Inflammatory Disorders; Stimuli-Responsive Systems; Theranostics; Nanomedicine; Combination Therapy; Pharmacokinetics; Precision Medicine.

Received: Jan. 08, 2026 **Revised: Feb. 15, 2026** **Accepted: March. 22, 2026** **Published: April 10, 2026**

DOI: https://doi.org/10.64062/JPGMB.Vol2.Issue2.2

https://jpgmb.com/1/issue/archive

1. Introduction

Hybrid nanocomposites have rapidly emerged as one of the most versatile and powerful classes of nanomaterials in modern pharmacology. These engineered structures combine two or more distinct materials—typically polymers, lipids, metals, ceramics, or carbon-based components—into a single nanoscale platform, enabling synergistic physicochemical and biological properties that surpass those of conventional single-material nanoparticles [1-2]. The rationale behind such hybridization lies in its ability to integrate multiple functionalities, such as enhanced drug loading, stimuli responsiveness, targeted delivery, and improved biocompatibility, within one unified system. As precision medicine continues to shape the future of therapeutic innovation, hybrid nanocomposites offer a strategic advantage by tailoring therapeutic and diagnostic capabilities to patient-specific needs. This is especially relevant in the management of high-burden diseases such as cancer and chronic inflammatory disorders, where complex pathophysiology demands multifunctional and adaptable treatment approaches. Given these clinical challenges and the growing interest in advanced nanosystems, this review aims to provide a comprehensive overview of hybrid nanocomposites, highlighting their design principles, mechanisms, therapeutic applications, and future potential in addressing unmet medical needs [3-4].

2. Fundamentals of Hybrid Nanocomposites

Hybrid nanocomposites represent a broad and diverse class of nanosystems that integrate two or more material types to achieve enhanced performance in pharmacological applications. These platforms can be classified into several major categories, including organic–inorganic hybrids, polymer–lipid assemblies, metal–polymer composites, ceramic–polymer blends, and biologically derived hybrids that incorporate proteins, polysaccharides, or other biomolecules [5-6]. Their versatility arises from key physicochemical properties such as tunable size, controlled surface charge, high structural stability, and the ability to encapsulate or conjugate multiple therapeutic agents. At the core of their functionality lies the principle of synergy: the combined materials exhibit superior characteristics compared to each component alone. This synergy may be structural—improving mechanical integrity; functional—integrating targeting ligands, imaging agents, or stimuli-responsiveness; or therapeutic—offering co-delivery, multimodal therapy, or enhanced bioavailability. Surface engineering further amplifies these benefits through functionalization strategies such as PEGylation, ligand conjugation, and charge modulation, allowing precise control over biodistribution, cellular uptake, and immune interactions. Together, these fundamental attributes position hybrid nanocomposites as powerful tools for addressing complex pharmacological challenges [7-8].

3. Fabrication Techniques

The fabrication of hybrid nanocomposites relies on a suite of chemical, physical, biological, and microfluidic methods that determine their structure, functionality, and clinical potential.

3.1 Chemical Synthesis

Chemical routes remain central to producing well-defined hybrid nanocomposites with controlled composition. Sol–gel processes enable the formation of organic–inorganic networks at mild conditions, making them ideal for metal or ceramic integration. Co-precipitation offers a straightforward method to synthesize uniform nanosystems, particularly metal–polymer and inorganic hybrids, through controlled nucleation and growth. Microemulsion and reverse micelle methods provide excellent control over particle size and morphology by confining reactions within nanoscale droplets, making them useful for fabricating monodisperse and compositionally complex nanocomposites [9-10].

3.2 Physical Methods

Physical fabrication strategies provide alternative routes for tailoring architecture and assembling multilayered hybrid structures. Electrospinning produces nanofibrous composites that combine polymers with inorganic or metal components, offering high surface area and tunable porosity for sustained drug delivery. Layer-by-layer assembly enables precise deposition of alternating organic and inorganic layers to create customizable, multifunctional coatings or capsules. Thin film deposition techniques, including sputtering and thermal evaporation, allow the formation of highly uniform hybrid films used in implant coatings, biosensors, and localized drug-release platforms.

3.3 Green and Bioinspired Synthesis

Green and bioinspired methods are gaining momentum due to their eco-friendly nature and biocompatibility. Plant extract–based synthesis uses phytochemicals as reducing and stabilizing agents, enabling mild fabrication of metal or metal-oxide hybrids. Enzyme-assisted approaches harness biological catalysts to direct polymerization or mineralization processes with remarkable specificity. Biomimetic mineralization replicates natural processes such as bone or shell formation, producing ceramic–biopolymer hybrids with superior biological affinity and structural organization [11-12].

3.4 Microfluidic and Continuous-Flow Approaches

Microfluidic and continuous-flow platforms represent the next frontier in nanocomposite manufacturing, offering unparalleled control over particle size, morphology, and material composition. These systems enable rapid mixing, precise reaction control, and reproducible synthesis of complex hybrid structures. Their inherent scalability—achieved through parallelization and continuous processing—positions microfluidic fabrication as a promising solution for industrial-scale production of advanced nanocomposites for clinical use [13]. Figure 1



Figure 1: Schematic Overview of Hybrid Nanocomposites for Cancer and Inflammatory Disorders

4. Hybrid Nanocomposites in Cancer Therapy

Hybrid nanocomposites have emerged as powerful platforms in cancer therapy due to their ability to integrate targeting, therapy, and diagnostics within a single nanosystem. In targeted drug delivery, these hybrids are frequently engineered with receptor-specific ligands—such as folate, RGD peptides, transferrin, and antibodies—to actively direct drugs toward tumor cells. Such active targeting complements passive targeting mediated by the enhanced permeability and retention (EPR) effect, collectively improving accumulation at the tumor site and minimizing off-target toxicity. Beyond targeting, hybrid nanocomposites are particularly suited for combination therapy, where multiple therapeutic modalities can be co-delivered or integrated within one carrier. Examples include chemo–photothermal systems that pair cytotoxic drugs with heat-generating nanomaterials, chemo–photodynamic hybrids that combine oxygen-dependent ROS generation with chemotherapy, and chemo–gene therapy constructs capable of simultaneously delivering nucleic acids and chemotherapeutic agents for synergistic tumor suppression [14-15].

These platforms are also central to imaging-guided theranostics. By incorporating components such as iron oxide, gold nanoparticles, or fluorescent dyes, hybrid nanocomposites can support MRI, CT, or fluorescence imaging, enabling real-time tracking of biodistribution, tumor accumulation, and therapeutic response. This integration of therapy and diagnostics enhances precision and treatment personalization. Importantly, hybrid nanocomposites provide unique strategies to overcome multidrug resistance (MDR), a major barrier in effective cancer management. They can inhibit efflux pumps, modulate intracellular drug retention, or utilize redox-responsive and pH-responsive mechanisms to achieve controlled drug release within the acidic, reductive tumor microenvironment. Together, these attributes position hybrid nanocomposites as next-generation multifunctional weapons against cancer [16-17].

5. Hybrid Nanocomposites for Inflammatory Disorders

Hybrid nanocomposites also hold significant promise for treating inflammatory disorders, where complex pathophysiology demands multifunctional therapeutic strategies. For anti-inflammatory drug delivery, hybrid carriers enable controlled and sustained release of agents such as NSAIDs, corticosteroids, or biologics, improving therapeutic outcomes while reducing systemic side effects. Their structural versatility makes them ideal platforms for encapsulating sensitive anti-inflammatory drugs and ensuring localized delivery at inflamed tissues.

In addition, immunomodulatory nanocomposites have gained traction for their ability to modulate immune responses at the cellular and molecular levels. These systems can regulate cytokine expression, suppress hyperactive immune signaling, or reprogram macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype—an approach particularly beneficial for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Hybrid nanocomposites also play a pivotal role in combating oxidative stress through antioxidant and ROS-scavenging mechanisms. Cerium oxide–based hybrids exhibit dynamic redox cycling capabilities, while polyphenol–metal nanocomposites provide potent antioxidative protection, mitigating tissue damage in inflammatory microenvironments [18-19].

Beyond pharmacological modulation, hybrid nanocomposites contribute to tissue repair and regeneration. Bioactive scaffolds incorporating inorganic nanoparticles, collagen, chitosan, or ceramics promote cellular attachment, angiogenesis, and extracellular matrix remodeling. Hybrid hydrogels, meanwhile, provide soft, hydrated environments suitable for wound healing, cartilage repair, and regenerative therapies. Across these applications, hybrid nanocomposites deliver a unique blend of therapeutic, protective, and regenerative capabilities that make them exceptionally valuable for managing and healing inflammatory disorders.

6. Stimuli-Responsive and Smart Hybrid Platforms

Stimuli-responsive hybrid nanocomposites represent a major leap forward in precision drug delivery, enabling therapeutic activation specifically at diseased sites while minimizing systemic exposure. pH-responsive hybrids take advantage of the acidic microenvironment in tumors or inflamed tissues, where acidic conditions trigger drug release through polymer swelling, bond cleavage, or charge reversal. Redox-sensitive platforms incorporate disulfide linkages or redox-active materials that respond to elevated intracellular glutathione levels, ensuring selective payload release inside cancer cells. Magnetically controlled hybrid systems utilize magnetic nanoparticles embedded within polymeric or lipid matrices, allowing remote manipulation, targeted accumulation, and even hyperthermia therapy using external magnetic fields. Light-responsive hybrids—often based on gold nanostructures, upconversion nanoparticles, or photosensitizers—enable on-demand drug release or photothermal/photodynamic activation with exceptional spatiotemporal precision. Enzyme-triggered hybrids further enhance specificity by exploiting disease-associated enzymes such as matrix metalloproteinases, phospholipases, or esterases, which degrade specific linkers or matrix components to initiate drug release. Collectively, these smart platforms provide highly controlled and context-specific therapeutic actions, positioning hybrid nanocomposites at the forefront of next-generation precision medicine [20-21].

7. Pharmacokinetics, Biodistribution, and Toxicology

Understanding the pharmacokinetics and toxicology of hybrid nanocomposites is crucial for their safe and effective translation into clinical applications. However, ADME profiling remains challenging due to the complex, multi-material nature of these constructs. Each component—polymer, lipid, metal, ceramic, or biological material—can influence circulation time, cellular uptake pathways, tissue accumulation, and clearance mechanisms. The integration of different materials often results in non-linear or unpredictable biodistribution patterns compared with traditional single-material nanoparticles. Material composition, surface chemistry, and particle morphology play significant roles in determining biological fate, including interactions with serum proteins, activation of the mononuclear phagocyte system, and transport across physiological barriers.

Long-term safety is another critical concern. While many organic components are biodegradable, inorganic materials such as metals or ceramics may persist in tissues, leading to potential accumulation, oxidative stress, or organ dysfunction over time. Evaluating biodegradation pathways, degradation by-products, and chronic toxicity is essential for regulatory approval [21-22]. Immunogenicity also remains a key challenge, as hybrid nanocomposites can trigger unwanted immune responses depending on their surface properties or residual fabrication reagents. Off-target effects, including unintended accumulation in healthy tissues, further emphasize the need for rigorous in vivo characterization. Overall, comprehensive PK, biodistribution, and toxicological assessments are indispensable for ensuring the clinical viability of hybrid nanocomposites as multifunctional therapeutic platforms [23-24].

8. Preclinical and Clinical Translation

The translation of hybrid nanocomposites from laboratory innovation to clinical reality depends heavily on robust preclinical evaluation and well-defined regulatory pathways. Preclinical studies commonly employ in vitro cell-based assays, 3D tumor spheroids, co-culture inflammatory models, and advanced organotypic systems to assess cytotoxicity, immunomodulation, biodistribution, and therapeutic efficacy. In vivo validation typically involves rodent models—including xenografts, orthotopic tumor models, genetically engineered mice, and inflammation-induced disease models—providing insight into pharmacokinetics, tissue accumulation, and therapeutic performance. Although still emerging, several hybrid nanocomposite platforms have progressed into clinical trials, particularly those combining polymers with lipids or inorganic components for cancer imaging, photothermal therapy, and combination drug delivery. These early-stage studies highlight both the promise and the complexities associated with multifunctional nanosystems [25-36].

Successful clinical translation requires strict adherence to GMP and regulatory guidelines. Regulatory agencies demand precise characterization of each component in the hybrid system, including stability, degradation products, and interactions between organic and inorganic phases. Manufacturing remains a significant challenge due to the need for scalable, reproducible processes capable of maintaining tight control over particle size, composition, and surface properties. Batch-to-batch variability, contamination risks, and the complexity of integrating multiple materials into a stable formulation often hinder industrial adoption. Overcoming these barriers will demand improved manufacturing platforms, standardized protocols, and clearer regulatory frameworks tailored to hybrid nanotechnologies [27-28].

9. Future Trends and Opportunities

The future of hybrid nanocomposites is poised for major breakthroughs as emerging technologies reshape how nanosystems are designed, optimized, and deployed in medicine. AI-driven design tools are rapidly gaining traction, enabling predictive modeling of material combinations, drug release behavior, and biological interactions. These computational approaches can dramatically shorten development timelines and enhance precision in tailoring hybrid systems for specific diseases. Personalized nanomedicine is another transformative direction, where hybrid nanocomposites can be engineered using patient-specific biomarkers, genetic profiles, or immune signatures to achieve highly individualized therapeutic responses.

Multifunctional “all-in-one” nanoplatforms represent a major opportunity, integrating targeting, therapy, imaging, and biosensing capabilities within one construct. Such platforms are particularly promising for combination immunotherapy, where hybrid nanocomposites can co-deliver immune modulators, antigens, adjuvants, or checkpoint inhibitors to orchestrate robust and coordinated immune responses against tumors or chronic inflammatory diseases. Additionally, the integration of hybrid nanomaterials with organ-on-chip technologies and real-time biosensing systems opens exciting avenues for high-throughput screening, toxicity testing, and personalized therapeutic modeling. Together, these advancements signal a future in which hybrid nanocomposites become central to precision therapeutics, adaptive drug delivery, and next-generation biomedical engineering [29-30].

10. Conclusion

Hybrid nanocomposites have emerged as powerful multifunctional platforms with the capacity to reshape modern pharmacology, offering unprecedented versatility in addressing the complex therapeutic needs of cancer and inflammatory disorders. By integrating organic, inorganic, and biological components into a single nanosystem, these hybrids enable synergistic improvements in drug delivery, targeting specificity, imaging capabilities, and controlled release. Their ability to simultaneously address multiple pathological pathways—while incorporating diagnostic, therapeutic, and protective functions—positions them as transformative tools in precision medicine.

Looking forward, the potential of hybrid nanocomposites to revolutionize the management of cancer and inflammatory diseases is immense. Their adaptability allows them to overcome traditional treatment barriers, such as multidrug resistance, poor drug bioavailability, and uncontrolled inflammation. As the field advances, the incorporation of stimuli-responsive behavior, immunomodulatory features, and theranostic properties will further elevate their clinical relevance. Coupled with emerging technologies like AI-driven design, patient-specific formulations, and organ-on-chip testing, hybrid nanocomposites are likely to play a central role in next-generation personalized therapeutics.

Nonetheless, significant challenges remain before these systems achieve widespread clinical adoption. Issues related to large-scale manufacturing, reproducibility, long-term safety, and regulatory compliance must be addressed through standardized protocols and advanced production technologies. Continued interdisciplinary collaboration and rigorous preclinical-to-clinical evaluation will be essential for bridging these gaps. Ultimately, with sustained research and strategic development, hybrid nanocomposites hold the promise of becoming key enablers of safer, smarter, and more effective treatments for some of the most pressing diseases of our time.

References

1. Malhotra, B. D., & Ali, M. A. (2018). Nanocomposite materials. In *Nanomaterials for Biosensors* (pp. 145–159). Elsevier. https://doi.org/10.1016/B978-0-323-44923-6.00005-4

2. Gutierrez, A. M., Frazar, E. M., Klaus, M. V., Paul, P., & Hilt, J. Z. (2022). Hydrogels and hydrogel nanocomposites: Enhancing healthcare through human and environmental treatment. *Advanced Healthcare Materials, 11*(7). https://doi.org/10.1002/adhm.202101820

3. Kannan, P., & Maduraiveeran, G. (2023). Carbon nanocomposites-based electrochemical sensors and biosensors for biomedical diagnostics. *Current Medicinal Chemistry, 30*. https://doi.org/10.2174/0929867330666230425163520

4. NHS England. (2023). *Widespread clinical support for reforming NHS cancer standards to speed up diagnosis for patients*. Cancer, 2023, 1.

5. Dhas, N., Kudarha, R., Garkal, A., et al. (2021). Molybdenum-based hetero-nanocomposites for cancer therapy, diagnosis and biosensing applications: Current advancement and future breakthroughs. *Journal of Controlled Release, 330*, 257–283. https://doi.org/10.1016/j.jconrel.2020.12.015

6. Deshwal, A., Kukreja, E. A., Shrivastava, N., Sheikh, F. A., Amna, T., & Tripathi, R. M. (2023). Nanomaterial applications in cancer therapy and diagnosis. In *Interaction of Nanomaterials with Living Cells* (pp. 471–484). Springer Nature Singapore. https://doi.org/10.1007/978-981-99-2119-5_16

7. Wang, J., Sui, L., Huang, J., et al. (2021). MoS_2-based nanocomposites for cancer diagnosis and therapy. *Bioactive Materials, 6*(11), 4209–4242. https://doi.org/10.1016/j.bioactmat.2021.04.021

8. Li, J., Yao, M., Shao, Y., & Yao, D. (2018). The application of bio-nanotechnology in tumor diagnosis and treatment: A view. *Nanotechnology Reviews, 7*(3), 257–266. https://doi.org/10.1515/ntrev-2018-0011

9. Vasanthakumar, A., Rejeeth, C., Vivek, R., et al. (2022). Design of bio-graphene-based multifunctional nanocomposites exhibiting intracellular drug delivery in cervical cancer treatment. *ACS Applied Bio Materials, 5*(6), 2956–2964. https://doi.org/10.1021/acsabm.2c00280

10. Yuan, Y. G., & Gurunathan, S. (2017). Combination of graphene oxide–silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells. *International Journal of Nanomedicine, 12*, 6537–6558. https://doi.org/10.2147/IJN.S125281

11. Kumar, S., Shukla, M. K., Sharma, A. K., et al. (2023). Metal-based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy. *MedComm, 4*(2). https://doi.org/10.1002/mco2.253

12. Mundekkad, D., & Cho, W. C. (2022). Nanoparticles in clinical translation for cancer therapy. *International Journal of Molecular Sciences, 23*(3), 1685. https://doi.org/10.3390/ijms23031685

13. Chauhan, S., Al-Dayan, N., Kumar, R., et al. (2022). Synthesis and characterization of novel bimetallic-semi-aromatic polyester nanocomposites for possible biomedical use. *Materials Letters, 306*, 130943. https://doi.org/10.1016/j.matlet.2021.130943

14. Carrera Espinoza, M. J., Lin, K. S., Weng, M. T., Kunene, S. C., Lin, Y. S., & Wu, C. M. (2023). Synthesis and characterization of supermagnetic nanocomposites coated with pluronic F127 as a contrast agent for biomedical applications. *Pharmaceutics, 15*(3), 740. https://doi.org/10.3390/pharmaceutics15030740

15. Elderdery, A. Y., Alhamidi, A. H., Elkhalifa, A. M. E., et al. (2022). Synthesis and characterization of ZnO–TiO_2–chitosan–escin metallic nanocomposites: Evaluation of their antimicrobial and anticancer activities. *Green Processing and Synthesis, 11*(1), 1026–1039. https://doi.org/10.1515/gps-2022-0086

16. Mariadoss, A. V. A., Saravanakumar, K., Sathiyaseelan, A., & Wang, M. H. (2020). Preparation, characterization and anticancer activity of graphene oxide–silver nanocomposite. *Journal of Photochemistry and Photobiology B, 210*, 111984. https://doi.org/10.1016/j.jphotobiol.2020.111984

17. Elderdery, A. Y., Alzahrani, B., Hamza, S. M. A., et al. (2022). Synthesis, characterization, and antiproliferative effect of CuO–TiO_2–chitosan–amygdalin nanocomposites in human leukemic MOLT4 cells. In S. Rethinam (Ed.), *Bioinorganic Chemistry and Applications* (Vol. 2022, pp. 1–13). https://doi.org/10.1155/2022/1473922

18. Tarhan, T., Tural, B., & Tural, S. (2019). Synthesis and characterization of new branched magnetic nanocomposite for loading and release of topotecan anticancer drug.

Journal of Analytical Science and Technology, 10(1), 30. https://doi.org/10.1186/s40543-019-0189-x

19. Țucureanu, V., Obreja, C. A., Pachiu, C., Brîncoveanu, O., & Matei, A. (2023). Synthesis and characterization of nanocomposites based on carbon materials and transitional oxides. In *IOCN 2023* (p. 8). MDPI. https://doi.org/10.3390/IOCN2023-14453
20. Asghar, K., Qasim, M., Dharmapuri, G., & Das, D. (2020). Thermoresponsive polymer-gated and superparamagnetic nanoparticle-embedded hollow mesoporous silica nanoparticles as smart multifunctional nanocarriers for targeted and controlled delivery of doxorubicin. *Nanotechnology, 31*(45), 455604. https://doi.org/10.1088/1361-6528/ab8b0e
21. Viswanathan, V., Laha, T., Balani, K., Agarwal, A., & Seal, S. (2006). Challenges and advances in nanocomposite processing techniques. *Materials Science and Engineering R: Reports, 54*(5–6), 121–285. https://doi.org/10.1016/j.mser.2006.11.002
22. Naghib, S. M., Zare, Y., & Rhee, K. Y. (2020). A facile and simple approach to synthesis and characterization of methacrylated graphene oxide nanostructured polyaniline nanocomposites. *Nanotechnology Reviews, 9*(1), 53–60. https://doi.org/10.1515/ntrev-2020-0005
23. Pacioni, N. L., Molina Torres, M. A., & Núñez, R. N. (2019). Synthesis and characterization of nanomaterials for biomedical applications. In *Nanoengineering Materials for Biomedical Uses* (pp. 13–34). Springer. https://doi.org/10.1007/978-3-030-31261-9_2
24. Timerbaev, A. R., Kuznetsova, O. V., & Keppler, B. K. (2021). Current trends and challenges in analysis and characterization of engineered nanoparticles in seawater. *Talanta, 226*, 122201. https://doi.org/10.1016/j.talanta.2021.122201
25. Alrushaid, N., Khan, F. A., Al-Suhaimi, E. A., & Elaissari, A. (2023). Nanotechnology in cancer diagnosis and treatment. *Pharmaceutics, 15*(3), 1025. https://doi.org/10.3390/pharmaceutics15031025
26. Jin, C., Wang, K., Oppong-Gyebi, A., & Hu, J. (2020). Application of nanotechnology in cancer diagnosis and therapy: A mini-review. *International Journal of Medical Sciences, 17*(18), 2964–2973. https://doi.org/10.7150/ijms.49801
27. Pourmadadi, M., Rajabzadeh-Khosroshahi, M., Eshaghi, M. M., et al. (2023). TiO_2-based nanocomposites for cancer diagnosis and therapy: A comprehensive review. *Journal of Drug Delivery Science and Technology, 82*, 104370. https://doi.org/10.1016/j.jddst.2023.104370
28. Kyriakides, T. R., Raj, A., Tseng, T. H., et al. (2021). Biocompatibility of nanomaterials and their immunological properties. *Biomedical Materials, 16*(4), 042005. https://doi.org/10.1088/1748-605X/abe5fa

29. Chiticaru, E. A., Damian, C. M., Pilan, L., & Ioniță, M. (2023). Label-free DNA biosensor based on reduced graphene oxide and gold nanoparticles. *Biosensors, 13*(8), 797. https://doi.org/10.3390/bios13080797

30. Ashraf, M. A., Peng, W., Zare, Y., & Rhee, K. Y. (2018). Effects of size and aggregation/agglomeration of nanoparticles on the interfacial/interphase properties and tensile strength of polymer nanocomposites. *Nanoscale Research Letters, 13*(1), 214. https://doi.org/10.1186/s11671-018-2624-0